115 related articles for article (PubMed ID: 19885269)
1. The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes.
Fahrbach J; Jacober S; Jiang H; Martin S
J Diabetes Sci Technol; 2008 Sep; 2(5):831-8. PubMed ID: 19885269
[TBL] [Abstract][Full Text] [Related]
2. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
[TBL] [Abstract][Full Text] [Related]
3. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.
Buse JB; Wolffenbuttel BH; Herman WH; Shemonsky NK; Jiang HH; Fahrbach JL; Scism-Bacon JL; Martin SA
Diabetes Care; 2009 Jun; 32(6):1007-13. PubMed ID: 19336625
[TBL] [Abstract][Full Text] [Related]
4. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
[TBL] [Abstract][Full Text] [Related]
5. The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine.
Buse JB; Wolffenbuttel BH; Herman WH; Hippler S; Martin SA; Jiang HH; Shenouda SK; Fahrbach JL
Diabetes Care; 2011 Feb; 34(2):249-55. PubMed ID: 21270182
[TBL] [Abstract][Full Text] [Related]
6. Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes.
Jovanovič L; Peters AL; Jiang HH; Hardin DS
Aging Clin Exp Res; 2014 Apr; 26(2):115-21. PubMed ID: 24092662
[TBL] [Abstract][Full Text] [Related]
7. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
8. [Starting an insulin regimen with insulin lispro mix 25 versus glargine insulin for type 2 diabetes].
Fernández Landó L; Massari F; Oviedo A; Jiang H
Medicina (B Aires); 2012; 72(3):235-42. PubMed ID: 22763161
[TBL] [Abstract][Full Text] [Related]
9. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
[TBL] [Abstract][Full Text] [Related]
10. Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts.
Giugliano D; Tracz M; Shah S; Calle-Pascual A; Mistodie C; Duarte R; Sari R; Woo V; Jiletcovici AO; Deinhard J; Wille SA; Kiljanski J
Diabetes Care; 2014 Feb; 37(2):372-80. PubMed ID: 24170763
[TBL] [Abstract][Full Text] [Related]
11. Comparison of insulin lispro mix 25 with insulin lispro mix 50 as insulin starter in Chinese patients with type 2 diabetes mellitus (CLASSIFY study): Subgroup analysis of a Phase 4 open-label randomized trial.
Su Q; Liu C; Zheng H; Zhu J; Li PF; Qian L; Yang WY
J Diabetes; 2017 Jun; 9(6):575-585. PubMed ID: 27371341
[TBL] [Abstract][Full Text] [Related]
12. Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial.
Rojas A; Sposetti G; Gross JL; Barbieri DE; Duan R; Linetzky B; De Lana JM; Stempa O; Rodriguez A
Diabetol Metab Syndr; 2016; 8():69. PubMed ID: 27660663
[TBL] [Abstract][Full Text] [Related]
13. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy.
Rosenstock J; Ahmann AJ; Colon G; Scism-Bacon J; Jiang H; Martin S
Diabetes Care; 2008 Jan; 31(1):20-5. PubMed ID: 17934150
[TBL] [Abstract][Full Text] [Related]
14. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HbA1c in Chinese patients with type 1 or type 2 diabetes randomized to twice daily insulin lispro low mix 25 or twice daily human insulin mix 30/70.
Li Y; Li Q; Li CJ; Wang CJ; Zheng YM; Issa M; Zhang J
Chin Med J (Engl); 2009 Nov; 122(21):2540-6. PubMed ID: 19951567
[TBL] [Abstract][Full Text] [Related]
16. Impact of diet on the efficacy of insulin lispro mix 25 and insulin lispro mix 50 as starter insulin in East Asian patients with type 2 diabetes: Subgroup analysis of the Comparison Between Low Mixed Insulin and Mid Mixed Insulin as Starter Insulin For Patients with Type 2 Diabetes Mellitus (CLASSIFY Study) randomized trial.
Chen W; Qian L; Watada H; Li PF; Iwamoto N; Imori M; Yang WY
J Diabetes Investig; 2017 Jan; 8(1):75-83. PubMed ID: 27287069
[TBL] [Abstract][Full Text] [Related]
17. Comparison of insulin lispro mix 25 with insulin lispro mix 50 as an insulin starter in Asian patients with type 2 diabetes: a phase 4, open-label, randomized trial (CLASSIFY study).
Watada H; Su Q; Li PF; Iwamoto N; Qian L; Yang WY
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155890
[TBL] [Abstract][Full Text] [Related]
18. Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients.
Hirsch IB; Yuan H; Campaigne BN; Tan MH
Endocr Pract; 2009; 15(4):343-8. PubMed ID: 19454394
[TBL] [Abstract][Full Text] [Related]
19. Impact of race/ethnicity on efficacy and safety of two starter insulin regimens in patients with type 2 diabetes: a posthoc analysis of the DURABLE trial.
Davidson JA; Wolffenbuttel BH; Arakaki RF; Caballero AE; Jiang HH; Hardin DS
Ethn Dis; 2013; 23(4):393-400. PubMed ID: 24392599
[TBL] [Abstract][Full Text] [Related]
20. Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes.
Yamashiro K; Ikeda F; Fujitani Y; Watada H; Kawamori R; Hirose T
J Diabetes Investig; 2010 Aug; 1(4):149-53. PubMed ID: 24843424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
